OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. 202-215
Open Access | Times Cited: 185
Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. 202-215
Open Access | Times Cited: 185
Showing 1-25 of 185 citing articles:
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Stephen M. Ansell, John Radford, Joseph M. Connors, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 4, pp. 310-320
Open Access | Times Cited: 210
Stephen M. Ansell, John Radford, Joseph M. Connors, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 4, pp. 310-320
Open Access | Times Cited: 210
Hodgkin lymphoma
Joseph M. Connors, Wendy Cozen, Christian Steidl, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 157
Joseph M. Connors, Wendy Cozen, Christian Steidl, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 157
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Peter Borchmann, Annette Plütschow, Carsten Kobe, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 2, pp. 223-234
Closed Access | Times Cited: 134
Peter Borchmann, Annette Plütschow, Carsten Kobe, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 2, pp. 223-234
Closed Access | Times Cited: 134
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial
David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 6, pp. e410-e421
Closed Access | Times Cited: 131
David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 6, pp. e410-e421
Closed Access | Times Cited: 131
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
Stefan Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, et al.
Nature (2023) Vol. 625, Iss. 7996, pp. 778-787
Open Access | Times Cited: 50
Stefan Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, et al.
Nature (2023) Vol. 625, Iss. 7996, pp. 778-787
Open Access | Times Cited: 50
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 6, pp. 755-781
Open Access | Times Cited: 130
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 6, pp. 755-781
Open Access | Times Cited: 130
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 322-334
Open Access | Times Cited: 59
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 322-334
Open Access | Times Cited: 59
Classical Hodgkin lymphoma
Pauline Brice, É. de Kerviler, Jonathan W. Friedberg
The Lancet (2021) Vol. 398, Iss. 10310, pp. 1518-1527
Open Access | Times Cited: 58
Pauline Brice, É. de Kerviler, Jonathan W. Friedberg
The Lancet (2021) Vol. 398, Iss. 10310, pp. 1518-1527
Open Access | Times Cited: 58
Spatial and molecular profiling of the mononuclear phagocyte network in Classic Hodgkin lymphoma
Benjamin Stewart, Martin Fergie, Matthew D. Young, et al.
Blood (2023)
Closed Access | Times Cited: 28
Benjamin Stewart, Martin Fergie, Matthew D. Young, et al.
Blood (2023)
Closed Access | Times Cited: 28
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
Ronald Boellaard, Irène Buvat, Christophe Nioche, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 9, pp. 1343-1348
Closed Access | Times Cited: 9
Ronald Boellaard, Irène Buvat, Christophe Nioche, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 9, pp. 1343-1348
Closed Access | Times Cited: 9
The role of PET/CT in the modern treatment of Hodgkin lymphoma
Jan Maciej Zaucha, Stéphane Chauvie, Renata Zaucha, et al.
Cancer Treatment Reviews (2019) Vol. 77, pp. 44-56
Closed Access | Times Cited: 66
Jan Maciej Zaucha, Stéphane Chauvie, Renata Zaucha, et al.
Cancer Treatment Reviews (2019) Vol. 77, pp. 44-56
Closed Access | Times Cited: 66
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kara M. Kelly, Peter D. Cole, Qinglin Pei, et al.
British Journal of Haematology (2019) Vol. 187, Iss. 1, pp. 39-48
Open Access | Times Cited: 64
Kara M. Kelly, Peter D. Cole, Qinglin Pei, et al.
British Journal of Haematology (2019) Vol. 187, Iss. 1, pp. 39-48
Open Access | Times Cited: 64
Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 5, pp. 1125-1125
Open Access | Times Cited: 49
Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 5, pp. 1125-1125
Open Access | Times Cited: 49
Self-intensified synergy of a versatile biomimetic nanozyme and doxorubicin on electrospun fibers to inhibit postsurgical tumor recurrence and metastasis
Yongwei Hu, Yanteng Xu, Rachel L. Mintz, et al.
Biomaterials (2022) Vol. 293, pp. 121942-121942
Closed Access | Times Cited: 34
Yongwei Hu, Yanteng Xu, Rachel L. Mintz, et al.
Biomaterials (2022) Vol. 293, pp. 121942-121942
Closed Access | Times Cited: 34
Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 10, pp. 1091-1101
Open Access | Times Cited: 30
Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 10, pp. 1091-1101
Open Access | Times Cited: 30
Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances
Faryal Munir, Viney Hardit, Irtiza Sheikh, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10095-10095
Open Access | Times Cited: 21
Faryal Munir, Viney Hardit, Irtiza Sheikh, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10095-10095
Open Access | Times Cited: 21
Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab
Aiping Chen, Fatima‐Zohra Mokrane, Lawrence H. Schwartz, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 5, pp. 649-654
Open Access | Times Cited: 43
Aiping Chen, Fatima‐Zohra Mokrane, Lawrence H. Schwartz, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 5, pp. 649-654
Open Access | Times Cited: 43
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
Alessandro Barbato, Grazia Scandura, Fabrizio Puglisi, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 42
Alessandro Barbato, Grazia Scandura, Fabrizio Puglisi, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 42
FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
Conrad‐Amadeus Voltin, Jasmin Mettler, Jirka Grosse, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 601-601
Open Access | Times Cited: 41
Conrad‐Amadeus Voltin, Jasmin Mettler, Jirka Grosse, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 601-601
Open Access | Times Cited: 41
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID ‐19 pandemic
Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal (2020) Vol. 50, Iss. 6, pp. 667-679
Closed Access | Times Cited: 41
Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Internal Medicine Journal (2020) Vol. 50, Iss. 6, pp. 667-679
Closed Access | Times Cited: 41
Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
Marc André, Patrice Carde, Simonetta Viviani, et al.
Cancer Medicine (2020) Vol. 9, Iss. 18, pp. 6565-6575
Open Access | Times Cited: 40
Marc André, Patrice Carde, Simonetta Viviani, et al.
Cancer Medicine (2020) Vol. 9, Iss. 18, pp. 6565-6575
Open Access | Times Cited: 40
Guideline for the first‐line management of Classical Hodgkin Lymphoma — A British Society for Haematology guideline
George Follows, Sally F. Barrington, Kaljit Bhuller, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 5, pp. 558-572
Open Access | Times Cited: 25
George Follows, Sally F. Barrington, Kaljit Bhuller, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 5, pp. 558-572
Open Access | Times Cited: 25
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
Jean Galtier, Laëtitia Vercellino, Loïc Chartier, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 171-180
Open Access | Times Cited: 25
Jean Galtier, Laëtitia Vercellino, Loïc Chartier, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 171-180
Open Access | Times Cited: 25
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
Juan Pablo Alderuccio, Russ Kuker, Fei Yang, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 640-657
Closed Access | Times Cited: 15
Juan Pablo Alderuccio, Russ Kuker, Fei Yang, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 640-657
Closed Access | Times Cited: 15
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
Theodoros P. Vassilakopoulos, Chrysovalantou Chatzidimitriou, John Asimakopoulos, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1071-1071
Open Access | Times Cited: 41
Theodoros P. Vassilakopoulos, Chrysovalantou Chatzidimitriou, John Asimakopoulos, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1071-1071
Open Access | Times Cited: 41
